Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of Niemann-Pick disease (NP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…
Regional Forecast is an add on offering from Clarivate’s Company & Drugs (C&D) that renders extended coverage of existing C&D proprietary data. With increasing demand to analyze the data in much…
*NOTE: the brochure was already reviewed by an editor* MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in…
MARKET OUTLOOK The HIV therapy market is crowded with many approved antiretroviral (ARV) therapies. Growth in this market is being driven by increasing acceptance of new, high-priced ARVs,…
Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
In 2020, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2020, sales of branded biologics in ophthalmology reached over $8.56 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period,…
In 2020, sales of branded biologics for respiratory indications reached nearly $1.5 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029…
In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…
In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…